Its pipeline also includes Claudin 18.2-directed ADC BMS-986476 in phase 2 for gastrointestinal and pancreatic cancer, acquired as a result of its acquisition of Turning Point Therapeutics for $4. ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Compared to previously launched biosimilars, these therapeutics are gaining market ... This could be an important turning point for manufacturers, such as Boehringer Ingelheim and Pfizer, that ...

VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph ...

This progress indicates a strong pipeline and potential for positive ... These factors contribute to the Buy rating as Beam Therapeutics continues to lead innovation in its field.

Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025 Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025 ...

Exclusive agreement to acquire Nudge Therapeutics includes their series ... and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its recent pipeline progress and anticipated 2025 milestones.

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew ...

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its recent pipeline progress and anticipated 2025 milestones.

New York, USA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Myocardial Infarction Clinical Trial Pipeline Appears Robust With 45+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...